Dyspnea

28

Pipeline Programs↗

7

Active Trials↗

14

Companies Involved↗

Dyspnea is an emerging landscape with 28 programs across 14 companies. The most active players are INSYS Therapeutics Inc, Eli Lilly, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 8 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

84/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

INSYS Therapeutics Inc

1 program

Eli Lilly

1 program

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Validus Pharmaceuticals

1 program

Hanmi Pharmaceutical Company Limited

1 program

Hikma Pharmaceuticals LLC

2 programs

Analysis

Modality Breakdown

97%

Small molecule

29 of 30 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.

Analysis

Trial Status

33

clinical trials

Completed21 · 64%

Recruiting3 · 9%

Active, not recruiting3 · 9%

Withdrawn2 · 6%

Terminated2 · 6%

Not yet recruiting1 · 3%

Other1 · 3%

Clinical Trials

Trial Activity

33 trials

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

Recruiting·VVA Office of Research and Development·Phase 2·NCT05937854·126 enrolled

Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma

Recruiting·FFoundation University Islamabad·N/A·NCT06609941·32 enrolled

The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases

Recruiting·UUniversity Hospital Hradec Kralove·Phase 2/3·NCT06252454·102 enrolled

Dexamethasone in Controlling Dyspnea in Patients With Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03367156·135 enrolled

Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 3·NCT04188418·150 enrolled

Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD

Active, not recruiting·IIstanbul Medeniyet University·N/A·NCT07058259·60 enrolled

129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation

Not yet recruiting·WWestern University, Canada·Phase 4·NCT07192016·60 enrolled

Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI

Completed·SSeoul National University Hospital·N/A·NCT02395991·60 enrolled

Inhaled Ondansetron & Dyspnea

Completed·MMcGill University·Phase 1·NCT01851993·30 enrolled

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators

Completed·—·Phase 4·NCT03405090·20 enrolled

Morphine for Treatment of Dyspnea in Patients With COPD

Completed·MMaastricht University Medical Center·Phase 4·NCT02429050·124 enrolled

Non Opioid Treatment for Experimental Dyspnea

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01577407·15 enrolled

Validation of an Observational Scale of Dyspnea in Non-communicating Patients in the ICU

Completed·AAssociation pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil·N/A·NCT02801838·50 enrolled

Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01856114·36 enrolled

Morphine or Fentanyl for Refractory Dyspnea in COPD

Completed·—·Phase 4·NCT03834363·59 enrolled

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)